CasNo.936623-90-4,99% up by HPLC Sacubitril Valsartan Sodium/ LCZ696 936623-90-4,(936623-90-4) Suppliers

25 Kilogram	Negotiable

Min.Order :25 Kilogram
Purity: 99% up by HPLC
Payment Terms : L/C,D/A,D/P,T/T

Keywords

Sacubitril Valsartan Sodium LCZ696 Sacubitril Valsartan

Quick Details

Appearance:White powder
Application:API
PackAge:1kg/bag ;5kg/drum:25KG/drum
ProductionCapacity:10|Metric Ton|Month
Storage:
Transportation:cool

Superiority:

Why is SINOWAY:
1) Specialized in pharmaceutical and healthcare industrial since 1987
2) ISO 9001:2015 & SGS audited supplier .
3) Accept various payment terms : T.T 30-60 days.
4) We have warehouse in USA with quickly shipment .
5) We can do different terms of FOB ,CIF/CIP ,DDP ...

Details:

Product name	Sacubitril Valsartan sodium/ LCZ696
CAS No.	936623-90-4
Molecular Formula	2(C24H29N5O3).2(C24H29NO5).5(H2O).6Na
Molecular Weight	958.008
Molecular Structure
Quality Standard	98% up by HPLC with total impurities < 0.05%
Appearance	White or almost white powder

ANALYSIS	SPECIFICATION	RESULTS
Appearance	White or almost white powder	White powder
Identification	IR: Spectrum should correspond to reference substance	Conforms
	UV: Spectrum should correspond to reference substance	Conforms
	XRPD: Spectrum should correspond to reference substance	Conforms
Water	4.0% - 5.9%	4.96%
Heavy metals	≤10ppm	Conforms
Stereoisomers	SCB(S,S) ≤ 0.15%	N.D.
	SCB(S,R) ≤ 0.15%	N.D.
	SCB(R,R) ≤ 0.15%	N.D.
	VST impurity A ≤ 0.5%	N.D.
Related substance	SCB impurity A ≤ 0.10%	N.D.
	SCB Impurity B ≤ 0.10%	N.D.
	SCB Impurity C ≤ 0.10%	N.D.
	SCB Impurity D ≤ 0.10%	N.D.
	SCB Impurity E ≤ 0.10%	N.D.
	Other single impurity ≤ 0.10%	0.05%
	Total impurities ≤ 1.0%	0.05%
Sodium	7.17% - 7.93%	7.30%
Assay	Sacubitril: 43.5%-46.5%	44.5%
	Valsartan: 46.2%-49.2%	47.4%
	Sacubitril valsartan sodium: 98.0% -101.5%	99.2%
Conclusion	The product meets In-house specification

What is Sacubitril Valsartan Sodium

Sacubitril Valsartan Sodium（LCZ696） is a type of drug that is commonly used to treat heart failure. It is a combination of two different drugs, Sacubitril and Valsartan, which work together to help improve the function of the heart.

Sacubitril is a neprilysin inhibitor that blocks the breakdown of brain natriuretic peptide (BNP) and its related peptides. This helps to increase levels of these peptides in the blood, which then help to relax blood vessels and reduce blood pressure. Valsartan is an angiotensin II receptor blocker (ARB) that blocks the action of angiotensin II on its receptors. Angiotensin II is a hormone that constricts blood vessels and increases blood pressure. By blocking the action of angiotensin II, Valsartan helps to relax blood vessels and reduce blood pressure.

Sacubitril Valsartan Sodium is used to treat patients with heart failure who have reduced ejection fraction, which means that the heart is not pumping blood effectively. It is thought to help improve heart function by blocking the breakdown of BNP and reducing blood pressure.

The safety and effectiveness of Sacubitril Valsartan Sodium has been established in clinical trials, and it is currently approved for use in many countries worldwide.